# Sanofi (SNY) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Pharmaceuticals. Price $45.33, market value $108.6 billion.

## Valuation
- **P/E (trailing): 22.6×** (5-yr avg 8.3×, 3-yr avg 9.1×). Sanofi trades at 22.6× trailing earnings, well above its own five-year average of 8.3×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 8.5×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.19**. A PEG of 0.19 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 2.0×**. Each dollar of revenue is priced at 2.0×.
- **Price / book: 1.3×**. The shares trade at 1.3× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 12.6×**. Enterprise value is 12.6× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 7.2%**. Free cash flow equals 7.2% of the market value. Above 5% is generally attractive.
- **Earnings yield: 4.4%**. The inverse of the P/E: 4.4% of the price is earned each year.

## Profitability
- **Gross margin: 72.8%**. Sanofi keeps 72.8% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 20.6%**. 20.6% of revenue is left after running the business, a healthy level in most sectors.
- **Return on equity: 10.9%**. 10.9% on shareholders' equity is solid.
- **Return on invested capital: 10.0%**. Return on all capital, debt included, is 10.0%.
- **Return on assets: 3.1%**. Each dollar of assets produces 3.1% of profit.

## Growth
- **EPS growth (1 yr): 43.8%** (3-yr -1.5%/yr, 5-yr -8.2%/yr). Earnings per share rose 43.8%.

## Financial health
- **Debt to equity: 0.20**. Debt is 0.20 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.8×**. It would take 0.8 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: 13.8×**. Operating profit covers interest 13.8× over, a safe margin.
- **Current ratio: 1.09** (quick 1.09). Current assets cover the next year's liabilities 1.09 times.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 5.34%** ($2.42 per share, trailing). Sanofi yields 5.34%, an income-level yield.
- **Consecutive years of increases: 2**. 2 straight years of increases.
- **Dividend growth (5 yr): 4.8%/yr** (1-yr 8.6%). The dividend has grown 4.8% a year over five years.

## Analyst view
- **Analyst consensus: buy** (9 analysts). 9 analysts cover Sanofi; the consensus is buy, with an average price target of $53.48 (+18% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -4.9%** (YTD -0.8%, 3-mo 6.1%). The shares are down 4.9% over twelve months including dividends.
- **From 52-week high: -14.0%** (16.0% above the low). Trading 14% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 73**. An RSI of 73 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 0.25** (volatility 23%). Beta of 0.25 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SNY · Page: https://foliofundamentals.com/stocks/sny

Not investment advice.